Phase II Trial of Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
The purpose of this phase II research is to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in patients with microsatellite stable pancreatic cancer.
Study ID: 19-587
Trial Phase: Phase II
Trial Sponsor: Bristol-Myers Squibb, Massachusetts General Hospital
Therapies Used in This Trial: Radiation Therapy, Ipilimumab, Nivolumab